Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

Professor Günter Höglinger, Lead Investigator of the Mascot trial, said: “Completing randomization of a global Phase 3 trial in MSA is a significant achievement for the field.” He added: “Advancing ...

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the ...

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...

Theravance Biopharma (TBPH) stock is in focus as the firm halts the clinical program for rare disease therapy ampreloxetine following a trial setback. Read more here.

Alterity Therapeutics has outlined three priorities for 2026 following the successful completion in 2025 of a Phase II trial of ATH434 in Multiple System Atrophy. Alterity outlines three priorities ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Ireland-incorporated Theravance Biopharma has announced top-line results from the Phase III CYPRESS study of ampreloxetine in ...